A Phase 1/2 interventional study of Stereotactic ablative radiation therapy in Renal Cell Carcinoma, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by University of Texas Southwestern Medical Center · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Carcinoma, Renal Cell · University of Texas Southwestern Medical Center.
Among the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, this one is the only one that started in 2015, is the only one in phase 1/2, and was the 1st registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →5 of the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 21 across the 9 interventional studies, 97 across the 1 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
5 of the studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05319015University of Texas Southwestern Medical CenterNeoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | 2026-12 |
| NCT02473536University of Texas Southwestern Medical CenterNeo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | 2027-01 |
| NCT04623502University of Texas Southwestern Medical CenterAn Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | 2027-04-30 |
| NCT05931393University of Texas Southwestern Medical CenterSequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | 2027-09-01 |
| NCT06601296University of Texas Southwestern Medical CenterRadiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and feasibility of pre-operative SABR of RCC IVC tumor thrombus.
To evaluate the effect of pre-operative SABR in RCC IVC tumor thrombus on relapse free survival at one year.
Stereotactic Ablative Radiation Therapy (SABR): 5 fractions of 8 Gy or 3 fractions of 12Gy. The concept of stereotactic radiosurgery involves tightly conforming dose of therapeutic radiation confined to a small region of the body. This results in eradication or ablation of the target tumor with sparing of surrounding normal tissues. The largest experience with stereotactic radiosurgery is for the treatment of intracranial tumors Neoadjuvant treatment of IVC-TT with SABR may decrease local recurrences and lower the likelihood of embolic complications and systemic metastasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any number of disease is allowed in the Pilot phase of the trial
Any serum Albumin is allowed, but ≥ 3.4 g/dL is strongly encouraged
Any serum is allowed but serum AST ≤ 34 IU/L is strongly encouraged
Women of and men must agree to use adequate (hormonal such as birth control pills, patch or ring; Depo-Provera, Implanon or barrier method, such as condom or diaphragm used with a spermicide of birth control; abstinence) prior to study entry, for the duration of study treatment, and for 90 days following completion of radiation therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
10.1 A female of childbearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SABR
Radiation: Stereotactic ablative radiation therapy
SABR
To determine the feasibility of neoadjuvant SABR followed immediately by IVC tumor thrombectomy
The treatment duration will be between 2-3 weeks depending on the fraction scheme chosen.
Time frame: 90 days
To determine the operative safety of neoadjuvant SABR followed immediately by IVC tumor thrombectomy
The treatment duration will be between 2-3 weeks depending on the fraction scheme chosen.
Time frame: 90 days
Survival at one year
Phase II To determine the relapse-free survival at one-year
Time frame: ONE YEAR
Peri-operative morbidity
To describe the associated peri-operative morbidity. Associated peri-operative morbidity is defined as grade\>2 side effects as assessed by NCI's CTCAE v4.0 toxicity within one year of surgery.
Time frame: 90 days
Adverse events post surgery
To determine the associated adverse events within one year of surgery. Associated adverse events are any toxicity as defined by NCI's CTCAE v4.0 toxicity criteria for the first year post- surgery.
Time frame: 1 year
Recurrence free survival (1 year)
To determine the 1 year recurrence free survival
Time frame: 1 year
Recurrence free survival overall
To determine the recurrence free survival
Time frame: 7 years
Recurrence
To determine the median time to recurrence
Time frame: 7 years
Pulmonary emboli
To determine the rate of pulmonary emboli within one year of surgery. Pulmonary Emboli: Pulmonary embolus determined in patients that become symptomatic and as a result has radiographic evidence of pulmonary embolus on CT angio or V/Q scan.
Time frame: 1 year
Pulmonary metastasis
To determine the rate of pulmonary metastasis. Pulmonary Metastasis: Any evidence of new lung metastasis \>1.0 cm • New lung nodules \>0.5cm will also be reported.
Time frame: 7 years
Systemic metastasis
To determine the rate of systemic metastasis. Systemic Metastasis: Any evidence of new metastasis that is progressing on a second scan \> 6 weeks apart
Time frame: 7 years
Overall survival
The rate of overall survival. Overall Survival: Time to death from the date of treatment start.
Time frame: 7 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2015 (actual). Primary completion is estimated for Jan 2027, 139 months after the start.
Of 41 non-industry phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 132. This study's planned 139 months is above that.
Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →